Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Abstract Text:

A G Gofman,I N Pyatnitskaya,Yu V Valentik,E N Krylov,O I Epstein,

The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times). Proproten-100 may used in combination with detoxicating and symptomatic drugs to treat patients with severe disorders. The preparation did not cause side effects. Our observations indicate that Proproten-100 may be used alone (monotherapy) or in combination with standard pharmaceutics for treatment of patients with the alcohol withdrawal syndrome.

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Publishing Authors By Initials

AG Gofman,IN Pyatnitskaya,YV Valentik,EN Krylov,OI Epstein,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bulletin of experimental biology and medicine

VOLUME: 135 Suppl 1

Page Numbers: 167-70

Journal Abbreviation: Bull. Exp. Biol. Med.

ISSN: 0007-4888

DAY: 1

MONTH: 09

YEAR: 2003

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372557

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.

AFFILIATION: Moscow Institute of Psychiatry, Russian Ministry of Health; Russian State Medical University; Russian Medical Academy of Postgraduate Education, Russian Ministry of Health; "Materia Medica Holding" Research-and-Production Company, Moscow.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bull Exp Biol Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome Related Publications

• A pharmacy benefit manager perspective.
• Analgesic and Antiinflammatory Activity of Antibodies to Histamine under Experimental Conditions.
• Antibodies to delta sleep-inducing Peptide in ultralow doses: study of the effect by enzyme immunoassay.
• Antiulcer Activity of Ultralow Doses of Antibodies to Histamine under Experimental Conditions.
• Changes in Immunological Parameters in Patients with Opium Abuse Receiving ANAR Therapy.
• Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
• Co-twin control designs for testing behavioral economic theories of child nutrition: methodological note.
• Coexistence, competition and hypercyclic interaction in some systems of biological interest.
• Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions.
• Effect of Potentiated Solutions on Mercury(II) Signal in Inversion Voltammetry.
• Effect of Preparations from Potentiated Ethanol on the Content of Biogenic Monoamines and Metabolism of Ethanol in Tissues of Rats during Alcoholization.
• Effect of allotransplantation of embryonic brain tissues and administration of potentiated antibodies to bombesin on hemodynamics in rats with emotional hypertension.
• Effect of antibodies to morphine in ultralow doses on induction of long-term potentiation in hippocampal slices from rats with chronic morphine dependence.
• Effect of potentiated antibodies to morphine on behavioral reactions in rats with morphine dependence.
• Effects of Potentiated Antibodies Against Brain-Specific S100 Protein on Biogenic Amine Content and Lipid Peroxidation in Rats under Conditions of Alcoholization.
• Effects of ultralow doses of antibodies to prostate-specific antigen on morphological and functional state of rat prostate.
• Efficiency of ultralow doses of antibodies to s100 protein and delta sleep-inducing Peptide in rats with anxious depression.
• Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
• Membranotropic effects of antibodies to s100 protein in ultralow doses.
• Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells.
• Potentiated Antibodies to Tumor Necrosis Factor-alpha in the Therapy of Patients with Rheumatoid Arthritis.
• Potentiated antibodies against morphine: effects on biogenic amines and lipid peroxidation in chronically morphinized rats.
• Potentiated cyclophosphane: experimental study of the effect on tumor development and efficiency of cytostatic therapy.
• Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.
• Regulatory activity of ultralow doses.
• Relationship between sex of parent and child on weight loss and maintenance in a family-based obesity treatment program.
• Reperfused myocardial infarction in mice: 3D mapping of late gadolinium enhancement and strain.
• The challenge of Down syndrome.
• Ultralow Doses of Anti-Idiotypic Antibodies to Human gamma-Interferon: Immunotropic Properties.
• Use of potentiated preparations to relieve alcohol and opium withdrawal syndromes.